Table 1 Baseline characteristics of the study participants
Intervention group (n = 320) | Control group (n = 340) | P value | |
|---|---|---|---|
Mean age, years | 69.9 | 69.3 | ns |
Women no. (%) | 130 (40.6) | 139 (40.9) | ns |
Qualifying event no. (%) | |||
Ischemic stroke | 181 (56.6) | 206 (60.6) | ns |
Intracerebral hematoma | 11 (3.4) | 12 (3.5) | ns |
TIA | 128 (40.0) | 122 (35.9) | ns |
mRS 3–5 no. (%) | 37 (11.6) | 31 (9.1) | ns |
Medical history no. (%) | |||
Stroke | 41 (12.9) | 37 (10.9) | ns |
Myocardial infarction | 22 (6.9) | 30 (8.8) | ns |
Heart failure | 8 (2.5) | 9 (2.6) | ns |
Atrial fibrillation | 47 (15.2) | 52 (15.4) | ns |
Diabetes | 45 (14.1) | 68 (20.1) | 0.049 |
Smoker no. (%) | 42 (13.1) | 48 (14.1) | ns |
Medications at 1 month no. (%) | |||
Antihypertensive drug | 231 (72.2) | 264 (77.6) | ns |
Statin | 253 (79.8) | 276 (81.7) | ns |
Antiplatelet drug | 253 (79.1) | 276 (81.2) | ns |
Anticoagulant drug | 48 (15.1) | 45 (13.3) | ns |
Baseline values ± SD | |||
SBP (mmHg) | 136.9 ± 16.7 | 137.2 ± 18.5 | ns |
DBP (mmHg) | 80.8 ± 11.6 | 80.2 ± 10.4 | ns |
LDL-C (mmol/L) | 2.5 ± 0.8 | 2.4 ± 0.8 | ns |